These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 31384888)

  • 1. Lessons from the renewal of the National Cervical Screening Program in Australia.
    Smith M; Hammond I; Saville M
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
    Lew JB; Feletto E; Wade S; Caruana M; Kang YJ; Nickson C; Simms KT; Procopio P; Taylor N; Worthington J; Smith D; Canfell K
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of Australia's renewed cervical screening program: Preparedness of general practitioners and nurses.
    Sultana F; Roeske L; Malloy MJ; McDermott TL; Saville M; Brotherton JML
    PLoS One; 2020; 15(1):e0228042. PubMed ID: 31995585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The National Bowel Cancer Screening Program: time to achieve its potential to save lives.
    Ee H; St John J
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.
    Lew JB; Simms KT; Smith MA; Hall M; Kang YJ; Xu XM; Caruana M; Velentzis LS; Bessell T; Saville M; Hammond I; Canfell K
    Lancet Public Health; 2017 Feb; 2(2):e96-e107. PubMed ID: 29253402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The early impacts of primary HPV cervical screening implementation in Australia on the pathology sector: a qualitative study.
    Bavor C; Brotherton JM; Smith MA; Prang KH; McDermott T; Rankin NM; Zammit CM; Jennett CJ; Sultana F; Machalek DA; Nightingale CE;
    BMC Health Serv Res; 2023 Oct; 23(1):1073. PubMed ID: 37803335
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Zammit CM; Creagh NS; McDermott T; Smith MA; Machalek DA; Jennett CJ; Prang KH; Sultana F; Nightingale CE; Rankin NM; Kelaher M; Brotherton JML
    Int J Environ Res Public Health; 2022 Nov; 19(23):. PubMed ID: 36497850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications.
    Hall MT; Smith MA; Lew JB; O'Hallahan J; Fentiman G; Neal H; Sage M; Canfell K
    Gynecol Oncol; 2019 Mar; 152(3):472-479. PubMed ID: 30876491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cervical cancer prevention in Australia: Planning for the future.
    Saville AM
    Cancer Cytopathol; 2016 Apr; 124(4):235-40. PubMed ID: 26619381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. History, development and future of cancer screening in Australia.
    Olver IN; Roder D
    Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use.
    Smith MA; Gertig D; Hall M; Simms K; Lew JB; Malloy M; Saville M; Canfell K
    BMC Health Serv Res; 2016 Apr; 16():147. PubMed ID: 27112193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Australian National Cervical Screening Program renewal: Attitudes and experiences of general practitioners, and obstetricians and gynaecologists.
    Obermair HM; Bennett KF; Brotherton JML; Smith MA; McCaffery KJ; Dodd RH
    Aust N Z J Obstet Gynaecol; 2021 Jun; 61(3):416-423. PubMed ID: 33512715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Routine cervical screening by primary HPV testing: early findings in the renewed National Cervical Screening Program.
    Machalek DA; Roberts JM; Garland SM; Thurloe J; Richards A; Chambers I; Sivertsen T; Farnsworth A
    Med J Aust; 2019 Aug; 211(3):113-119. PubMed ID: 31168828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.
    Velentzis LS; Caruana M; Simms KT; Lew JB; Shi JF; Saville M; Smith MA; Lord SJ; Tan J; Bateson D; Quinn M; Canfell K
    Int J Cancer; 2017 Dec; 141(12):2410-2422. PubMed ID: 28801947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. To expand coverage, or increase frequency: Quantifying the tradeoffs between equity and efficiency facing cervical cancer screening programs in low-resource settings.
    Campos NG; Tsu V; Jeronimo J; Mvundura M; Lee K; Kim JJ
    Int J Cancer; 2017 Mar; 140(6):1293-1305. PubMed ID: 27925175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
    Kim JJ; Burger EA; Sy S; Campos NG
    J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cervical cancer screening and management practices among providers in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP).
    Saraiya M; Irwin KL; Carlin L; Chen X; Jain N; Benard V; Montano DE
    Cancer; 2007 Sep; 110(5):1024-32. PubMed ID: 17628488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of primary HPV screening for cervical cancer in Germany--a decision analysis.
    Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
    Eur J Cancer; 2011 Jul; 47(11):1633-46. PubMed ID: 21482103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of increasing cervical cancer screening coverage in the Middle East: An example from Lebanon.
    Sharma M; Seoud M; Kim JJ
    Vaccine; 2017 Jan; 35(4):564-569. PubMed ID: 28017434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of replacing cytology with human papillomavirus testing for cervical cancer screening on the prevalence of
    Hui BB; Reulein CP; Guy RJ; Donovan B; Hocking JS; Law MG; Regan DG
    Sex Transm Infect; 2018 May; 94(3):216-221. PubMed ID: 29326178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.